Wed, Jan 28, 2015, 12:10 PM EST - U.S. Markets close in 3 hrs 50 mins

Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

  • posiedon59 posiedon59 Nov 21, 2013 11:48 AM Flag

    OMS302 is a Proprietry combination accepted for filing by FDA--Look up the word Proprietary!

    OMS302 is Omeros' product being developed for use during intraocular lens replacement (ILR), including cataract surgery and refractive lens exchange. OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent phenylephrine and the anti-inflammatory agent ketorolac. Omeros' New Drug Application (NDA) for OMS302 has been accepted for filing by the FDA and its Marketing Authorization Application (MAA) for OMS302 has been validated by the EMA.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • ..."look up the proprietary"????....uhhhhh, let's see -- oh, here it is: word commonly used by scamsters to make naive fools believe something is special in order to lighten the naive fools' wallets to the benefit of the scamster...

      ...looks like it's working, too!...HAW!!!!...

 
OMER
20.52-0.94(-4.38%)12:09 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.